No headlines found.
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 26-Mar 5:10 PM ET)
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer
Globe Newswire (Tue, 3-Feb 7:00 AM ET)
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Leonabio trades on the NASDAQ stock market under the symbol LONA.
As of April 20, 2026, LONA stock price climbed to $9.38 with 67,022 million shares trading.
LONA has a beta of -1.05, meaning it tends to be less sensitive to market movements. LONA has a correlation of 0.02 to the broad based SPY ETF.
LONA has a market cap of $88.11 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that LONA belongs to (by Net Assets): VTI, VXF, DFMC, DCOR.
LONA support price is $7.88 and resistance is $9.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LONA shares will trade within this expected range on the day.
